Biostem Technologies

BSEM · OTC

$1.64+$0.10 (+6.49%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.54

About BSEM

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The firm's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. The company also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.

Employees: 0
Headquarters: Pompano Beach, Florida
Listed: Jul 11, 2001
Sector: Health Care
Industry: Pharmaceuticals
Website: biostemtechnologies.com

Leadership

Biostem Technologies executives
Name	Title	Since	Age
Thomas Dugan	—	—	66
Jason Matuszewski	—	2018	38
Brandon Poe	—	2022	55
Andrew Van Vurst	—	2016	33
Michael Fortunato	—	—	57
Barry Hassett	—	2026	—
Patrick Daly	—	—	60
Kenneth Warrington	—	—	53

Similar companies

Companies in the same industry as Biostem Technologies

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.